Chemical structure of tacrine
Find information on thousands of medical conditions and prescription drugs.

Tacrine

Tacrine is a parasympathomimetic and a centrally acting cholinesterase inhibitor (anticholinesterase). It was the first centrally-acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease, and was first synthesised at the Department of Pharmacology at the University of Sydney. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Clinical uses

Tacrine was the prototypical cholinesterase inhibitor for the treatment of Alzheimer's disease. Its clinical effectiveness was hindered by poor oral bioavailability and considerable adverse drug reactions (including nausea, diarrhoea, urinary incontinence, and hepatotoxicity) such that few patients could tolerate therapeutic doses. Indeed there is some doubt as to its efficacy in humans at all.

Other newer cholinesterase inhibitors, such as donepezil, are now preferred over tacrine.

Sources

  • Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6

Read more at Wikipedia.org


[List your site here Free!]


Tolerance to tacrine, arterial hypotension and leuko-araiosis in Alzheimer's disease
From Age and Ageing, 9/1/98 by Florence Lebert

SIR--The baroreflex regulation of blood pressure is modulated by cholinergic systems [1]. Alzheimer's disease (AD) is more often associated with sympathetic dysfunction than fronto-temporal lobe dementia, in which the cholinergic system is relatively spared [2]. In patients with AD, orthostatic hypotension is associated with the severity of the cognitive decline--possibly because of chronic hypoperfusion of the white matter [3]. Orthostatic hypotension could also influence the response to cholinesterase inhibitors; Velnacrine non-responders had a more severe decrease in systolic postural blood pressure before treatment than responders [4].

Amar et al. [5] reported a high rate of withdrawal from tacrine in patients with AD with leuko-araiosis, especially because of agitation. We examined a possible relationship between tolerance to tacrine, orthostatic blood pressure and leuko-araiosis in patients with AD. Forty-one consecutive patients with AD with mild or moderate dementia were included. They were free from heart disease, diabetes mellitus or delirium. They were not taking any drugs with hypotensive side effects. Drug dosage had been stable for at least 1 month before the start of the study. Median age was 73.9 years (range 57-88), the median Mini-Mental State Examination score [6] was 19.6 (range 29-9) at baseline. Leuko-araiosis was ,assessed on computed tomography scan using Rezek's score [7].

Patients received 40 mg/day of tacrine for 6 weeks, 80 mg/day for 6 weeks, then 120 mg/day. Orthostatic hypotension (defined according to Bannister's criteria [8]) was noted at baseline and after 2 weeks of tacrine at 120 mg/day. The Mann-Whitney U-test was used for statistical analysis. Thirty-six patients were treated with tacrine without obvious side effects. Five patients (14%) were withdrawn prematurely: three because of gastritis and nausea, one because of agitation and one because of abnormal liver function tests. The age of withdrawn patients was higher than that of the others [80.2 years (73-88) versus 73.1 years (57-87); U = -1,97, P = 0.04]. The Rezek score did not differ between the groups: in withdrawn patients it was between 0 and 15 points. Seventeen patients had orthostatic hypotension: none was withdrawn. However, systolic blood pressure in supine position was significantly lower in withdrawn patients [123.6 mmHg (110-150) versus 142.6 mmHg (118-182); U = -2,43, P = 0.01]. Furthermore, orthostatic hypotension disappeared whilst on tacrine in 13 patients (42% versus 10%).

In conclusion, it appears that patients with low blood pressure have a lower tolerance of tacrine and that tacrine has an effect on orthostatic hypotension. A relationship between blood pressure dysregulation, cognitive decline, tolerance to anticholinesterase drugs in AD and white matter changes should be further investigated. Anticholinesterase drugs might also benefit patients with AD by decreasing orthostatic hypotension.

We would like to thank Didier Leys for his comments on this work.

[1.] Brezenoff HE. Cardiovascular regulation by brain acetylcholine. Fed Prac 1984; 43: 17-20.

[2.] Hasenbroekx C, Lebert F, Pasquier F et al. Autonomic failures in Alzheimer's disease and in frontotemporal dementia. Neurobiol Aging 1996; suppl. 17: S88.

[3.] Englund E, Brun A, Gustafson X et al. A white matter disease in dementia of Alzheimer's type--clinical and neuropathological corretater. Int J Geriatr Psychiatr 1989; 4: 87-102.

[4.] Pomara N, Deptula D, Singh R. Pretreatment postural blood pressure drop as a possible predictor response to the cholinesterase inhibitor velnacrine (HP 029) in Alzheimer's disease. Psychopharmacol Bull 1991; 27: 301-7.

[5.] Amar K, Wilcock GK, Scot M et al. The presence of leuko-araiosis in patients with Alzheimer's disease predicts poor tolerance to tactine, but does not discriminate responders from non-responders. Age Ageing 1997; 26: 25-9.

[6.] Folstein ME Folstein SE, McHugh PR. Mini Mental State: practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.

[7.] Rezek DL, Morris JC, Fulling KH et al. Periventricular white matter lucencies in senile dementia of the Alzheimer type and in normal aging. Neurology 1987; 37: 1365-8.

[8.] Bannister R, Mathias CJ. Autonomic Failure, third edition. Oxford: Oxford University Press, 1993.

FLORENCE LEBERT, CAROLE MOULY, FLORENCE PASQUIER

Memory Disorders Unit,

University Hospital of Lille (CHRU-Hopital B),

Lille, France

Fax: (+33) 3 28 43 47 98

COPYRIGHT 1998 Oxford University Press
COPYRIGHT 2000 Gale Group

Return to Tacrine
Home Contact Resources Exchange Links ebay